N-acetyl-4-(2-methylallyloxy)piperidine | 70978-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-acetyl-4-(2-methylallyloxy)piperidine
• 英文别名: N-Acetyl-4-(2-methylallyloxy)-piperidin；1-[4-(2-methylprop-2-enoxy)piperidin-1-yl]ethanone
• CAS: 70978-96-0
• 化学式: C₁₁H₁₉NO₂
• 分子量: 197.277
• InChiKey: LTYGUDAQJHOYQY-UHFFFAOYSA-N

物化性质

• 沸点：
  128 °C(Press: 1 Torr)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-acetyl-4-(2-methylallyloxy)piperidine 在 mercury(II) diacetate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-(2-hydroxy-2-methyl-n-propoxy)piperidine
  参考文献：
  名称：

  Antihypertensive

  摘要：

  心血管系统的调节剂，特别是治疗高血压的化学式为##STR1##的药用可接受的生物前体，以及其药用可接受的酸盐；其中R.sup.1和R.sup.2中的每一个是C.sub.1-4烷基或--CH.sub.2 CF.sub.3；alk是乙烯，单苯基取代的乙烯，单甲基和双甲基取代的乙烯或单苯基单甲基取代的乙烯；而R.sup.3是氢，C.sub.1-4烷基，C.sub.3-C.sub.6环烷基；苯基或取代苯基；以及它们的制备方法。

  公开号：

  US04237138A1
• 作为产物：
  描述：

  N-乙酰基-4-羟基哌啶 、 3-氯-2-甲基丙烯 生成 N-acetyl-4-(2-methylallyloxy)piperidine
  参考文献：
  名称：

  Antihypertensive

  摘要：

  心血管系统的调节剂，特别是治疗高血压的化合物，其化学式为##STR1## 及其药用可接受的生物前体和药用可接受的酸盐；其中R.sup.1和R.sup.2中的每一个是C.sub.1-4烷基或--CH.sub.2 CF.sub.3；alk是乙烯，单苯基取代的乙烯，单甲基和双甲基取代的乙烯或单苯基单甲基取代的乙烯；R.sup.3是氢，C.sub.1-4烷基，C.sub.3-C.sub.6环烷基；苯基或取代苯基；以及它们的制备方法。

  公开号：

  US04237138A1

文献信息

• 1-Piperidinophthalazines as cardiac stimulants
  申请人：Pfizer Inc.

  公开号：US04289772A1

  公开（公告）日：1981-09-15

  A series of 1-piperidinophthalazine derivatives as phosphodiesterase inhibitors and cardiac stimulants.

  一系列1-哌啶基喹唑啉衍生物作为磷酸二酯酶抑制剂和心脏兴奋剂。
• 2,4-Diamino-6,7-dimethoxyquinazolines. 4. 2-[4-(Substituted oxyethoxy)piperidino] derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents
  作者：Simon F. Campbell、John C. Danilewicz、Colin W. Greengrass、Rhona M. Plews

  DOI：10.1021/jm00398a006

  日期：1988.3

  A series of 4-amino-6,7-dimethoxy-2-[4-(substituted oxyethoxy)piperidino] quinazoline derivatives (2) was synthesized and evaluated for alpha-adrenoceptor affinity and antihypertensive activity. Most compounds showed binding affinities within the nanomolar range for alpha 1-receptors, although 25 and 26 showed enhanced potency (Ki, ca. 1.5 X 10(-10) M), equivalent to that of prazosin. Series 2 also displaced [3H]clonidine from alpha 2-adrenoceptors, but at relatively high doses of 10(-6) M, and selectivity for alpha 1 sites still predominated. In a rabbit pulmonary artery preparation, 12, 16, and 25 were potent antagonists of the alpha 1-mediated, postjunctional vasoconstrictor activity of norepinephrine with no effect at the prejunctional alpha 2 sites which modulate transmitter release. Physicochemical measurements gave a pKa of 7.63 +/- 0.10 for 12, and N-1 protonation will be favored (60%) at physiological pH to provide the alpha 1-adrenoceptor pharmacophore, 28. Antihypertensive activity of series 2 was evaluated following oral administration to spontaneously hypertensive rats, and blood pressure was measured after 1 and 6 h. Compounds 12, 13, 16, 23, and 37 displayed moderate efficacy and duration of action in lowering blood pressure, but the plasma half-life (ca. 2 h) of 16 in dogs was not compatible with potential once-daily administration in humans.
• CAMPBELL, SIMON F.;DANILEWICZ, JOHN C.;GREENGRASS, COLIN W.;PLEWS, RHONA +, J. MED. CHEM., 31,(1988) N 3, 516-520
  作者：CAMPBELL, SIMON F.、DANILEWICZ, JOHN C.、GREENGRASS, COLIN W.、PLEWS, RHONA +

  DOI：——

  日期：——
• US4237138A
  申请人：——

  公开号：US4237138A

  公开（公告）日：1980-12-02
• US4289772A
  申请人：——

  公开号：US4289772A

  公开（公告）日：1981-09-15